Last reviewed · How we verify
NCT05049044: OBSTINATE
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
trial testing Quality of Life Questionnaire-Core 30 (QLQ-C30) in Non-Small Cell Lung Cancer in 413 participants. Participants enrolled and being followed up; not accepting new ones.
30 June 2027
Quick facts
| Lead sponsor | Groupe Francais De Pneumo-Cancerologie |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 413 |
| Start date | 18 December 2020 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2027 |
| Sites | 34 locations across France |
Drugs / interventions tested
- Quality of Life Questionnaire-Core 30 (QLQ-C30)
Conditions studied
- Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
Sponsor
Groupe Francais De Pneumo-Cancerologie — full company profile →
Who can join
18 and older, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
OBSTINATE is an observational, national, prospective, multicentric study on Quality of life in patients with unresecable stade III non-small cell lung cancers. Locally advanced non-small cell lung cancers (NSCLCs with a Tumor, Node and Metastasis \[TNM\] stage III) patients represent approximately a third of newly discovered NSCLCs every year, and a very heterogeneous group of clinical situations. Therapies are multidisciplinary and very heterogeneous across oncology centers. Patients with locally advanced NSCLC have a high symptom burden that is known to affect their quality of life. Health-related quality of life (HR-QoL) is a specific and multidimensional type of patient-reported outcome (PRO) related to the physical, psychological and social impact of the disease and its treatment as perceived by patients. HR-QoL allows, together with data of efficacy and safety, a more complete assessment of risks and benefits of each treatment. Therefore, QoL maintenance is a valuable consideration for treatment decisions, especially in the rapidly evolving therapeutic landscape of unresectable NSCLC. The study is designed to collect PROs HR-QoL data from every new patient diagnosed with an unresectable stage III NSCLC over a period of 18 months. We also aim to describe clinical characteristics of these patients, the therapeutic strategies conducted, and outcomes in a "real-word" oncological practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05049044
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
- NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
Other Groupe Francais De Pneumo-Cancerologie trials
Trials by the same sponsor.
- NCT06620835 — Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Pres · Phase 2 · recruiting
- NCT06247826 — Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion · NA · recruiting
- NCT05308966 — Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and I · completed
- NCT05122806 — Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC · NA · recruiting
- NCT03305133 — Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (N · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05049044 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Groupe Francais De Pneumo-Cancerologie
- Last refreshed: 4 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05049044.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing